Ibrutinib for Lymphocytic Leukemia Prompts Skin and Nail Changes

Although generally well tolerated, ibrutinib, a Bruton tyrosine kinase inhibitor effective against chronic lymphocytic leukemia (CLL), may lead to nail and hair abnormalities, according to a new report.